JPMorgan analyst Anupam Rama initiated coverage of Travere Therapeutics with an Overweight rating and $26 price target. The analyst sees commercial momentum for Filspari and key near-term data for the product, as well as better Street appreciation for the potential of pegtibatinase in homocystinuria, as “upside levers” over the next 12-18 months for the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics to Report Second Quarter 2023 Financial Results
- Travere Therapeutics price target lowered to $35 from $37 at Canaccord
- Mirum to buy bile acid portfolio from Travere Therapeutics for $445M
- Travere to sell bile acid product portfolio for up to $445M to Mirum
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)